Compare · AMGN vs PMCB
AMGN vs PMCB
Side-by-side comparison of Amgen Inc. (AMGN) and PharmaCyte Biotech Inc. (PMCB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and PMCB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $251.89B, about 3494.9x PMCB ($72.1M).
- AMGN has been more active in the news (22 items in the past 4 weeks vs 3 for PMCB).
- AMGN has more recent analyst coverage (25 ratings vs 1 for PMCB).
- Company
- Amgen Inc.
- PharmaCyte Biotech Inc.
- Price
- -
- -
- Market cap
- $251.89B
- $72.1M
- 1M return
- +7.26%
- -
- 1Y return
- +36.21%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- News (4w)
- 22
- 3
- Recent ratings
- 25
- 1
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
PharmaCyte Biotech Inc.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.
Latest AMGN
- AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
- FDA Approval for KANJINTI issued to AMGEN INC
- Director Ishrak Omar was granted 152 shares, increasing direct ownership by 2% to 7,682 units (SEC Form 4)
- Director Holley Charles M was granted 185 shares, increasing direct ownership by 1% to 13,262 units (SEC Form 4)
- Director Gibbs David W was granted 278 shares (SEC Form 4)
- Director Drake Michael V was granted 114 shares, increasing direct ownership by 2% to 6,030 units (SEC Form 4)
- NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM
- Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
- FDA Approval for AMJEVITA issued to AMGEN INC
- REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY
Latest PMCB
- PharmaCyte Biotech Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- PharmaCyte Biotech Reports Strong Cash and Asset Position
- PharmaCyte Biotech, Inc. Announces Reverse Stock Split
- SEC Form 8-K filed by PharmaCyte Biotech Inc.
- SEC Form 10-Q filed by PharmaCyte Biotech Inc.
- SEC Form 10-K filed by PharmaCyte Biotech Inc.
- Amendment: SEC Form 4 filed by Director Weinstein Robert
- Amendment: SEC Form 4 filed by Director Walker Wayne Remell
- Amendment: SEC Form 4 filed by Director Abecassis Michael M
- Amendment: SEC Form 4 filed by Director Schechter Jonathan